Hemophagocytic lymphohistiocytosis (HLH) during childhood cancer treatment is a rare adverse event posing major diagnostic and therapeutic challenges. Between 1995 and 2006, 6 children developed HLH while on conventional chemotherapy (n=4) or after allogeneic stem cell transplantation (n=2). Treatment of HLH included dexamethasone and etoposide, 2 children additionally received infliximab or daclizumab. Three children survived, whereas 3 children died 2, 5, and 47 days after diagnosis of HLH. HLH is a severe adverse event of childhood cancer therapy. Early diagnosis and immediate initiation of adequate treatment are mandatory to overcome this severe condition. 
Introduction
Hemophagocytic lymphohistiocytosis (HLH) is an uncommon clinical entity characterized by fever, pancytopenia, hepatosplenomegaly and hemophagocytosis in bone marrow, liver or lymph nodes.
1 There are two distinct forms of HLH classified as primary and secondary HLH respectively. The primary, autosomal recessive form, also termed familial hemophagocytic lymphohistiocytosis (FHL), usually occurs in the first years of life and is fatal when untreated. Secondary HLH is associated with a variety of underlying diseases including infections, malignancies and autoimmune diseases. 2, 3 The precise pathophysiology of HLH must still be clarified. A major factor causing the manifestations of HLH might be an acquired dysregulation of T lymphocytes and natural killer cells resulting in excessive activation of hemophagocytic monocytes. 1, 2, 4 Recently, the HLH Study Group of the Histiocyte Society proposed diagnostic guidelines for HLH including fever, splenomegaly, cytopenia, hypertriglyceridemia, hypofibrinogenemia, hemophagocytosis, low/absent NK-cell activity, hyperferritinemia, and high soluble interleukin 2 receptor (s-IL2-receptor). 3 The clinical course of HLH is usually severe and life-threatening and immediate initiation of therapy is mandatory. Treatment aims to suppress the severe hyperinflammation by chemoimmunotherapy including corticosteroids, cyclosporine A and/or etoposide. 2, 3, 5 In patients with FHL and in patients with secondary HLH not responding to chemoimmunotherapy, stem cell transplantation (SCT) is a potentially curative treatment option.
6,7
Malignancy associated HLH (MAHS) usually occurs at initial presentation of malignancy, mainly in patients with leukemia or lymphoma, sometimes even masking the malignancy itself.
2,8-10
In contrast to MAHS, HLH may occasionally develop later during cancer treatment as a consequence of treatment-related immunosuppression. Data describing this distinct condition are extremely rare and treatment recommendations for these children are urgently needed. 2 We report on the clinical course of 6 children with various malignancies who developed HLH during antineoplastic treatment.
Design and Methods
Between 1995 and 2006, 508 consecutive children with various newly diagnosed malignancies were treated at the Division of Pediatric Hematology/Oncology of the Medical University of Graz. Among these, 6 patients (4 females and 2 males aged between 0.5 and 12.5 years) were diagnosed with HLH according to the criteria of the Histiocyte Society.
3 Family history of HLH was negative in all patients. A written informed consent was obtained from patients or their legal guardians. Treatment was performed according to the international treatment protocols approved by the Ethics committee. In addition, this specific study on HLH as severe adverse event complicating antineoplastic treatment was approved by the local Ethics committee. Patient characteristics and oncologic pre-treatment are summarized in Table 1 . Diagnoses included acute lymphoblastic leukemia (ALL) (n=2), acute myelogenous leukemia (AML) (n=2), recurrent medulloblastoma (n=1) and Ewing sarcoma (n=1). Four of the 6 patients were diagnosed with HLH during conventional hemato-oncologic treatment, whereas 2 patients developed HLH on day 57 and 24 after allogeneic stem cell transplantation (SCT). Stem cell donors were a matched unrelated donor (MUD) in patient 5 and the HLA identical mother in patient 6. Both received reduced intensity conditioning (RIC) including fludarabine and melphalan, followed by immunosuppressive treatment with prednisone and cyclosporine A. In addition, patient 5 received mycophenolate mofetil. At onset of HLH, all 6 patients underwent supportive care with granulocyte colony stimulating factor (G-CSF), broad spectrum antibiotics and antimycotics, blood transfusions and parenteral nutrition via central venous lines.
Results and Discussion

Diagnosis of HLH
All children initially presented with prolonged pancytopenia, hepatosplenomegaly and fever refractory to antimicrobial therapy. Three patients had CNS-symptoms including seizures, headache and encephalopathy with impaired vision/swallowing. Analysis of CSF showed pleocytosis and elevated protein, whereas MRI was normal in these patients. Different infectious agents were identified by PCR or antigen detection as presumed triggers of HLH including influenza A virus, Epstein Barr virus (EBV), cytomegalovirus (CMV), human herpes virus 6 (HHV6) and adenovirus. Two patients (patients 2 and 5) also presented infection with aspergillus fumigatus. Since there was no response to common supportive treatment, serum parameters providing the diagnosis of HLH were evaluated Table 2) .
Treatment of HLH and outcome
All patients underwent treatment of the presumed triggering infectious agents with immunoglobulines and specific antiviral drugs, e.g. amantadine (80 mg/kg/d for 5 days) for influenza A virus, gancyclovir (10 mg/kg/d for 10
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days) for CMV, HHV6 or EBV, ribavirine (33 mg/kg starting dose, then 4×16 mg/kg on day 2-5 followed by 3×8 mg/kg on day 6-14) for adenovirus, and liposomal amphotericin B ( , and is now, 2 years after BMT, clinically well without evidence of HLH or recurrent malignancy. Since 1969, some sporadic cases had been published describing an hemophagocytic syndrome as a rapidly progressive and fatal disease terminating the clinical course of patients with ALL or lymphoma (mainly T-cell type). This syndrome was variously called histiocytic medullary reticulosis (HMR), HMR-like syndrome, malignant histiocytosis and reactive hemophagocytic syndrome. [11] [12] [13] Since 1991, the term HLH is generally accepted to describe this condition. 3 The occurrence of HLH during antineoplastic treatment is still a very rare and usually fatal event. The registry of the BFM-ALL trials from 1981-2001 holds data on 4 out of 971 T-ALL patients who developed HLH and none of them survived.
14
In agreement with these data, only 1 out of 4 patients with HLH during conventional antineoplastic treatment survived this serious complication in our study. Interestingly, 2 of our patients had HLH as a complication of oncologic treatment for solid tumors. The occurrence of HLH in the setting of therapy for solid tumors has never been reported before, since so far HLH has only been seen in patients with leukemia or lymphoma. There are some case reports describing HLH as a complication after SCT. [15] [16] [17] Fludarabine based conditioning regimens are suspected to be additional non-specific triggers for HLH after SCT. 17 Interestingly, both of our 2 patients with HLH following SCT underwent RIC including fludarabine.
There are several problems and questions regarding the optimum management of children with HLH during antineoplastic treatment. Early diagnosis might be frequently Supported by these case reports, 2 of our patients were successfully treated with daclizumab and infliximab respectively. Some investigators suggest that cytokines (e.g. G-CSF), as well as prolonged intravenous nutrition including soluble lipids, might provide a continuous stimulation of the monocyte/macrophage system resulting in HLH.
3,20 It remains, therefore, debatable whether G-CSF and/or parenteral nutrition containing soluble fats should be given in patients with HLH.
In conclusion, HLH as a complication of antineoplastic treatment is still a rare and life-threatening serious adverse event. Early diagnosis by analysis of serum parameters and detection of hemophagocytosis in bone marrow is absolutely mandatory in order to immediately initiate adequate and aggressive treatment. The role of the new biologicals, including the monoclonal antibodies daclizumab and infliximab, remains to be defined. Further clinical data describing the clinical course and the management of children with HLH during antineoplastic treatment are urgently awaited.
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